Literature DB >> 21469978

Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.

Scott M Berry1, Kristine R Broglio, Donald A Berry.   

Abstract

IL-2 has been investigated as maintenance therapy for patients with AML in five randomized trials. None has shown a statistically significant benefit. A randomized trial of HDC + IL-2 showed a statistically significant benefit for leukemia-free survival (LFS) in comparison with standard of care. Because HDC + IL-2 has not been randomized against IL-2 alone, the question remains as to whether and to what extent HDC + IL-2 is an improvement compared to IL-2 alone. This is a literature-based meta-analysis. We employ two versions of a Bayesian hierarchical model to compare HDC + IL-2 versus IL-2 alone on the basis of LFS in patients in remission from AML.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21469978     DOI： 10.3109/07357907.2011.568563

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  13 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

Review 2.  Histamine receptors and cancer pharmacology: an update.

Authors:  Noelia A Massari; Melisa B Nicoud; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2018-12-13       Impact factor: 8.739

3.  A novel nomogram for peritoneal mesothelioma predicts survival.

Authors:  Nicholas P Schaub; Meghna Alimchandani; Martha Quezado; Phil Kalina; John S Eberhardt; Marybeth S Hughes; Tatiana Beresnev; Raffit Hassan; David L Bartlett; Steven K Libutti; James F Pingpank; Richard E Royal; Udai S Kammula; Prakash Pandalai; Giao Q Phan; Alexander Stojadinovic; Udo Rudloff; H Richard Alexander; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2012-12-12       Impact factor: 5.344

Review 4.  Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2014-06

5.  Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.

Authors:  Johan Aurelius; Anna Martner; Mats Brune; Lars Palmqvist; Markus Hansson; Kristoffer Hellstrand; Fredrik B Thoren
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 6.  TGF- β: an important mediator of allergic disease and a molecule with dual activity in cancer development.

Authors:  Belen Tirado-Rodriguez; Enrique Ortega; Patricia Segura-Medina; Sara Huerta-Yepez
Journal:  J Immunol Res       Date:  2014-06-11       Impact factor: 4.818

7.  Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.

Authors:  Gail J Roboz; Pau Montesinos; Dominik Selleslag; Andrew Wei; Jun-Ho Jang; Jose Falantes; Maria T Voso; Hamid Sayar; Kimmo Porkka; Paula Marlton; Antonio Almeida; Sanjay Mohan; Farhad Ravandi; Guillermo Garcia-Manero; Barry Skikne; Hagop Kantarjian
Journal:  Future Oncol       Date:  2016-01-19       Impact factor: 3.404

8.  Pathophysiological Role of Histamine H4 Receptor in Cancer: Therapeutic Implications.

Authors:  Melisa B Nicoud; Karina Formoso; Vanina A Medina
Journal:  Front Pharmacol       Date:  2019-06-05       Impact factor: 5.810

9.  Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Authors:  Anna Martner; Anna Rydström; Rebecca E Riise; Johan Aurelius; Harald Anderson; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

10.  Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2.

Authors:  Roberta Kiffin; Hanna Grauers Wiktorin; Malin S Nilsson; Johan Aurelius; Ebru Aydin; Brianna Lenox; Jonas A Nilsson; Anders Ståhlberg; Fredrik B Thorén; Kristoffer Hellstrand; Anna Martner
Journal:  Front Oncol       Date:  2018-06-18       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.